Adaptive Biotechnologies Corp (NASDAQ: ADPT) on Friday, soared 0.86% from the previous trading day, before settling in for the closing price of $4.64. Within the past 52 weeks, ADPT’s price has moved between $2.28 and $5.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 27.46%. The company achieved an average annual earnings per share of 22.02%. With a float of $142.33 million, this company’s outstanding shares have now reached $145.08 million.
The extent of productivity of a business whose workforce counts for 709 workers is very important to gauge. In terms of profitability, gross margin is 49.93%, operating margin of -109.49%, and the pretax margin is -126.53%.
Adaptive Biotechnologies Corp (ADPT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Adaptive Biotechnologies Corp is 3.49%, while institutional ownership is 96.65%. The most recent insider transaction that took place on Aug 22 ’24, was worth 121,079. In this transaction SVP and General Counsel of this company sold 26,922 shares at a rate of $4.50, taking the stock ownership to the 139,365 shares. Before that another transaction happened on Aug 22 ’24, when Company’s Officer proposed sale 26,922 for $4.50, making the entire transaction worth $121,079.
Adaptive Biotechnologies Corp (ADPT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 22.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.60% during the next five years compared to -32.91% drop over the previous five years of trading.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Trading Performance Indicators
Adaptive Biotechnologies Corp (ADPT) is currently performing well based on its current performance indicators. A quick ratio of 3.84 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.47, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.01 in one year’s time.
Technical Analysis of Adaptive Biotechnologies Corp (ADPT)
The latest stats from [Adaptive Biotechnologies Corp, ADPT] show that its last 5-days average volume of 0.92 million was inferior to 1.44 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 6.48%. Additionally, its Average True Range was 0.32.
During the past 100 days, Adaptive Biotechnologies Corp’s (ADPT) raw stochastic average was set at 60.25%, which indicates a significant increase from 6.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.27% in the past 14 days, which was lower than the 72.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.69, while its 200-day Moving Average is $3.88. Now, the first resistance to watch is $4.78. This is followed by the second major resistance level at $4.87. The third major resistance level sits at $4.95. If the price goes on to break the first support level at $4.61, it is likely to go to the next support level at $4.53. Assuming the price breaks the second support level, the third support level stands at $4.44.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Key Stats
Market capitalization of the company is 690.16 million based on 147,368K outstanding shares. Right now, sales total 170,280 K and income totals -225,250 K. The company made 43,190 K in profit during its latest quarter, and -46,220 K in sales during its previous quarter.
